News

Throughout November, landmarks around the world will be lighting up orange to raise awareness of chronic obstructive pulmonary disease (COPD). Nearly 80 landmarks will be illuminated across the U.S., Canada, Australia, New Zealand, and the U.K. in honor of COPD Awareness month, according to the COPD Foundation, which…

A single injection of the next-generation drug rademikibart markedly cut the rate and impact of acute exacerbations among adults with chronic obstructive pulmonary disease (COPD) over one month versus a placebo in a global clinical trial. That’s according to new data announced by therapy developer Connect Biopharma, which…

Apollo Therapeutics plans to launch a Phase 2 trial in the first half of 2027 to test whether its experimental vaccine APL-10456 can prevent disease flares in people with chronic obstructive pulmonary disease (COPD). According to a company press release, Apollo has completed enrollment and dosing in…

Choosing the right inhaler to deliver treatment for people with chronic obstructive pulmonary disease (COPD) may require considering their cognitive function, hand dexterity, and ability to breathe in forcefully, according to data from a large observational study in the U.S. Researchers found that nearly three in every 10 participants…

When levels of black carbon, or soot, in the air are high, walking outside can worsen cough and increase mucus production in people with chronic obstructive pulmonary disease (COPD), a new study shows. The researchers note that their findings do not change existing recommendations that people with COPD should…

AERO-007 — a combination of two classes of bronchodilators delivered via a standard jet nebulizer — led to rapid and clinically meaningful improvements in lung function among adults with moderate-to-severe chronic obstructive pulmonary disease (COPD). That’s according to data from the Phase 2a portion of a Phase 1/2a…

One year of treatment with tozorakimab, AstraZeneca’s experimental therapy, was reported to significantly reduce the annual rate of moderate-to-severe exacerbations, or periods of sudden symptom worsening, in adults with chronic obstructive pulmonary disease (COPD). These are the top-line results from the global Phase 3 MIRANDA clinical trial (NCT06040086),…

The experimental therapy tozorakimab from AstraZeneca was superior to a placebo at reducing the rate of moderate to severe exacerbations, or sudden episodes of symptom worsening, in adults with chronic obstructive pulmonary disease (COPD). That’s according to top-line, one-year data from two Phase 3 clinical trials —…

For people with chronic obstructive pulmonary disease (COPD), characterized by cough and shortness of breath, Anoro Elipta (umeclidinium-vilanterol) may work better than other approved COPD medications at reducing the risk of disease flares. That’s according to a new federally funded study that used U.S. insurance data to compare…

A novel test based on the levels and composition of certain proteins in mucus, called mucins, may help assess lung health in people with chronic obstructive pulmonary disease (COPD), according to a new study. Findings show that higher Mucin Quantitative Score (MUCQ) values were significantly associated with worse lung…